Sravanth Kumar Hindupur
Overview
Explore the profile of Sravanth Kumar Hindupur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dimitrakopoulos C, Hindupur S, Colombi M, Liko D, Ng C, Piscuoglio S, et al.
BMC Genomics
. 2021 Aug;
22(1):592.
PMID: 34348664
Background: Genetic aberrations in hepatocellular carcinoma (HCC) are well known, but the functional consequences of such aberrations remain poorly understood. Results: Here, we explored the effect of defined genetic changes...
2.
Saxena M, Balaji S, Deshpande N, Ranganathan S, Pillai D, Hindupur S, et al.
J Cell Sci
. 2018 Jun;
131(14).
PMID: 29950484
The developmental programme of epithelial-mesenchymal transition (EMT), involving loss of epithelial and acquisition of mesenchymal properties, plays an important role in the invasion-metastasis cascade of cancer cells. In the present...
3.
Dimitrakopoulos C, Hindupur S, Hafliger L, Behr J, Montazeri H, Hall M, et al.
Bioinformatics
. 2018 Mar;
34(14):2441-2448.
PMID: 29547932
Motivation: Several molecular events are known to be cancer-related, including genomic aberrations, hypermethylation of gene promoter regions and differential expression of microRNAs. These aberration events are very heterogeneous across tumors...
4.
Quintavalle C, Hindupur S, Quagliata L, Pallante P, Nigro C, Condorelli G, et al.
Cell Death Dis
. 2017 Oct;
8(10):e3138.
PMID: 29072691
Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related death with limited treatment options and frequent resistance to sorafenib, the only drug currently approved for first-line therapy. Therefore, better understanding...